Film-Coated Tablet without JNJ-77242113
Sponsors
Janssen - Cilag International, Janssen Cilag International
Conditions
Moderate to Severe Plaque PsoriasisPlaque PsoriasisUlcerative Colitis
Phase 2
Phase 3
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis involving Special Areas
Active, not recruitingCTIS2023-505122-34-00
Start: 2023-12-05Target: 146Updated: 2025-08-01
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment
Active, not recruitingCTIS2023-505120-59-00
Start: 2023-12-19Target: 281Updated: 2025-11-25
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
RecruitingCTIS2023-505121-14-00
Start: 2024-01-18Target: 320Updated: 2025-11-25
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
RecruitingCTIS2023-507039-39-00
Start: 2024-03-22Target: 392Updated: 2025-11-28
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
RecruitingCTIS2024-515706-77-00
Start: 2025-05-08Target: 399Updated: 2025-08-04